Clinical Trial Update: Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating paclitaxel in patients with refractory or recurrent acute leukemia or chronic myelogenous leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED